Full Text View
Tabular View
No Study Results Posted
Related Studies
Sarcoid Genetic Analysis (SAGA)
This study has been completed.
First Received: May 25, 2000   Last Updated: November 10, 2005   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00005542
  Purpose

To identify sarcoidosis susceptibility genes and to determine how these genes and environmental risk factors interact to cause sarcoidosis.


Condition
Lung Diseases
Sarcoidosis

MedlinePlus related topics: Sarcoidosis
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Defined Population

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: May 1999
Estimated Study Completion Date: April 2005
Detailed Description:

BACKGROUND:

Sarcoidosis is a rare systemic granulomatous disease that mainly affects young to middle aged adults, and more severely affects African Americans than Caucasians. The etiology of sarcoidosis is not yet known, and epidemiological studies have only identified general risk factors including age, sex, race, and family history. Sarcoidosis may also be influenced by environmental factors, although the particular environmental agents have not yet been clearly defined. While previous studies have provided evidence for familial clustering, little is known about the genes that influence predisposition to sarcoidosis.

DESIGN NARRATIVE:

This is a multicenter consortium genetic epidemiology study. The investigators will accomplish their goal by organizing a 10-site multi-center consortium to recruit an adequate sample of sarcoidosis families for analysis. They plan to use the affected sibling pair linkage analysis to scan the genome for linked chromosomal regions, transmission disequilibrium testing to evaluate candidate genes in those regions with evidence for linkage, and an environmental questionnaire to collect data to test for possible interactions of susceptibility genes with exogenous risk factors. Genotyping and analysis of data are scheduled to begin in July, 2001 with completion of all analysis by April, 2004.

The study consists of a Clinical Core, a Data Coordinating Core, and a Genetics Core with a DNA Processing Center and a Genotyping Center. Eight of the ten clinical centers comprising the Clinical Core are members of the ACCESS, A Case Control Etiology of Sarcoidosis Study.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005542

Sponsors and Collaborators
Investigators
Investigator: Michael Iannuzzi Henry Ford Hospital
  More Information

Publications:
Study ID Numbers: 5084
Study First Received: May 25, 2000
Last Updated: November 10, 2005
ClinicalTrials.gov Identifier: NCT00005542     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Lymphatic Diseases
Respiratory Tract Diseases
Lung Diseases
Sarcoidosis
Lymphoproliferative Disorders

Additional relevant MeSH terms:
Lymphatic Diseases
Respiratory Tract Diseases
Lung Diseases
Sarcoidosis
Lymphoproliferative Disorders

ClinicalTrials.gov processed this record on May 07, 2009